NovaGo Logo

Diabetic Retinopathy

Diabetic Retinopathy (DR) is the leading cause of legal blindness in working-age adults worldwide and is a common complication of Type 1 and Type 2 Diabetes. Current therapies are only partially effective at restoring edema-induced blurred vision and preventing vision loss in many patients; however, a substantial proportion (40%–50%) of patients with DR do not respond well or not at all to anti-VEGF treatment. All current therapies also fail to restore the compromised retinal vasculature and cannot stop the progressive neuronal degeneration.